TRISCEND: Six-Month Outcomes of Transfemoral Tricuspid Valve Replacement in Patients With Tricuspid Regurgitation
We Recommend
Disclosures
Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of patients with any cardiovascular disease to include devices, drugs, and digital health care products listed below:
- Equity/Stock(s)/Options (Institutional) - Dura Biotech; Thubrikar Aortic Valve Inc; MicroInterventional Devices; Supira
- Consultant Fee/Honoraria/Speaker's Bureau (Institutional) - Meril Lifesciences; JenaValve; Admedus (Equity as well)
- Grant Support/Research Contract (Institutional) - Edwards Lifesciences; Abbott Vascular; Medtronic; Boston Scientific Corporation; St. Jude Medical